J&JPRD obtains FDA complete response letter for bipolar disorder drug
The FDA has asked for additional information regarding the company’s supplemental new drug application (sNDA) for Risperdal Consta long-acting injection. The sNDA, submitted in April 2008, sought approval
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.